Quality-by-design-engineered mitochondrial targeted nanoparticles for glioblastoma therapy.

ABSTRACT: Glioblastoma (GB, IDH-wildtype) constitutes the most aggressive primary malignant neoplasm with limited treatment modalities due to the blood-brain barrier (BBB) often restricting drug delivery. It also has an overall low survival rate with no curative solution, reinforcing the need for innovative formulation development for effective management of GB. This study explores a novel approach using triphenylphosphonium (TPP⁺)-conjugated chitosan nanoparticles for targeted mitochondrial delivery of temozolomide (TMZ) to GB cells. The conjugated nanoparticles were designed to leverage chitosan's biocompatibility and TPP's mitochondrial targeting ability. TMZ-loaded chitosan nanoparticles were systematically developed and optimized employing a Quality-by-Design (QbD) approach with a sc

SUBMITTER: Dahifale A 

PROVIDER: S-EPMC11513785 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature